Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18757101 | 1.00 | FOLH1 (0.33) | FOLH1CHRM1TBXA2RADRA1AHTR7 | |
| SCHEMBL18660634 | 0.87 | CHRM1 (0.32) | FOLH1CHRM1TBXA2RADRA1AHTR7 | |
| SCHEMBL22939353 | 0.83 | FOLH1 (0.33) | FOLH1CHRM1TBXA2RADRA1AHTR7 | |
| SCHEMBL18631724 | 0.81 | L3MBTL1 (0.32) | FOLH1CHRM1TBXA2RADRA1AIDO1 | |
| SCHEMBL24023415 | 0.80 | FOLH1 (0.34) | FOLH1CHRM1TBXA2RADRA1AHTR7 | |
| SCHEMBL20510285 | 0.78 | FOLH1 (0.38) | FOLH1CHRM1TBXA2RADRA1AIDO1 | |
| SCHEMBL19191844 | 0.76 | FOLH1 (0.36) | FOLH1CHRM1TBXA2RADRA1AHTR7 | |
| SCHEMBL22355998 | 0.76 | ALOX15 (0.40) | FOLH1CHRM1TBXA2RADRA1AHTR7 | |
| SCHEMBL15413215 | 0.76 | FOLH1 (0.36) | FOLH1CHRM1TBXA2RADRA1AHTR7 | |
| SCHEMBL18631728 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9630917-B2 | Cysteamine prodrugs, pharmaceutical compositions thereof, and methods of use | Nguyen, Mark Quang (US) | 2017-04-25 | — | — | US | disclosed |
| US-20170081279-A1 | CYSTEAMINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081279-A1 | CYSTEAMINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | GLS, GLS2, CTH | FOLH1 241/4885CHRM1 1492/4885TBXA2R 3391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.